Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Multiple Myeloma 6Carcinoma, Hepatocellular 2Uveal Melanoma 1Prostatic Neoplasms 1Plasmacytoma 1Neoplasms, Plasma Cell 1Neoplasms 1Melanoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Immunoglobulin Light-chain Amyloidosis 1Carcinoma, Renal Cell 1Amyloidosis 1

Interventions

Ipilimumab 5Nivolumab 4pembrolizumab 3sargramostim 2fludarabine 2binimetinib 2aldesleukin 2Interleukin-2 2Granulocyte-Macrophage Colony-Stimulating Factor 2Cyclophosphamide 2trametinib 1tebentafusp 1sotrastaurin 1montanide ISA 51 1incomplete Freund's adjuvant 1glembatumumab vedotin 1fludarabine phosphate 1entrectinib 1Valproic Acid 1Tramadol 1Thalidomide 1Temozolomide 1Solutions 1Ruthenium-106 1Radiotherapy 1RNA, Messenger 1Protein Kinase C 1Melphalan 1Magnetic Resonance Spectroscopy 1Ibuprofen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Uveal Melanoma × Thalidomide × Clear all
NCT00005815 2013-06-19

Temozolomide and Thalidomide in Treating Patients With Stage III or Stage IV Melanoma

Memorial Sloan Kettering Cancer Center

Phase 1/2 Completed
Dermatologic

Uveal Melanoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡